Related Experiment Video
Updated: Mar 31, 2026

Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
Heparin protocols in cardiovascular surgery for antiphospholipid syndrome: a clinical case report
Tomohiro Nakajima1, Yutaka Iba2, Tsuyoshi Shibata2
1Sapporo Medical University, Sapporo, Japan. t.nakajima@sapmed.ac.jp.
Background:
Antiphospholipid syndrome (APS) is a prothrombotic disorder that presents significant challenges during cardiovascular surgery due to its high risk of both thrombotic and hemorrhagic complications. Perioperative management of anticoagulation, particularly with heparin, requires careful balancing to prevent catastrophic outcomes such as thromboembolism or excessive bleeding.
Case Presentation:
The patient was a 66-year-old man. Two years prior, he was diagnosed with deep vein thrombosis (DVT), and direct oral anticoagulant (DOAC) therapy was initiated. Further evaluation in the cardiology department revealed elevated anticardiolipin antibody levels, leading to a diagnosis of APS. While on DOAC therapy, he was found to have severe aortic valve stenosis caused by a bicuspid aortic valve and 45-mm dilation of the ascending aorta. Surgical intervention was deemed necessary, and the operation was performed. As activated clotting time (ACT) tends to be elevated in APS, intraoperative heparin concentration was closely monitored. The surgery proceeded without perioperative embolic events, and the patient had an uneventful postoperative course.
Conclusions:
We report a case of open-heart surgery in a patient with APS, where perioperative embolic events were successfully avoided through close monitoring of blood heparin concentrations.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management

